Search

Your search keyword '"Bruchfeld, Annette"' showing total 502 results

Search Constraints

Start Over You searched for: Author "Bruchfeld, Annette" Remove constraint Author: "Bruchfeld, Annette"
502 results on '"Bruchfeld, Annette"'

Search Results

2. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

4. Nomenclature in nephrology: preserving ‘renal’ and ‘nephro' in the glossary of kidney health and disease

5. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

6. Identification of proteinase 3 autoreactive CD4+T cells and their T-cell receptor repertoires in antineutrophil cytoplasmic antibody–associated vasculitis

7. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

8. Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

11. #1021 A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy

12. #3108 Rituximab in adult-onset IgA vasculitis

13. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

14. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

15. Rituximab in Membranous Nephropathy

17. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective.

18. Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease.

19. Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.

20. The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population.

21. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline

22. Augmented thrombin formation is related to circulating levels of extracellular vesicles exposing tissue factor and citrullinated histone-3 in anti-neutrophil cytoplasmic antibody-associated vasculitides

25. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

26. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

29. Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations

31. Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis

32. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

33. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial

35. Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.

36. Results of the first nationwide cohort study of outcomes in dialysis and kidney transplant patients before and after vaccination for COVID-19.

37. Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.

38. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

39. Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)

42. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

43. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

45. Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment.

46. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.

47. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study

48. Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?

49. Brain dysfunction in tubular and tubulointerstitial kidney diseases

50. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Catalog

Books, media, physical & digital resources